Related Experiment Video
Updated: Mar 9, 2026

Examining BCL-2 Family Function with Large Unilamellar Vesicles
Published on: October 5, 2012
Mitochondrial apoptosis and BH3 mimetics
Haiming Dai1,2,3, X Wei Meng1,2, Scott H Kaufmann1,2
1Division of Oncology Research , Mayo Clinic, Rochester, MN, 55905, USA.
Abstract:
The BCL2-selective BH3 mimetic venetoclax was recently approved for the treatment of relapsed, chromosome 17p-deleted chronic lymphocytic leukemia (CLL) and is undergoing extensive testing, alone and in combination, in lymphomas, acute leukemias, and solid tumors. Here we summarize recent advances in understanding of the biology of BCL2 family members that shed light on the action of BH3 mimetics, review preclinical and clinical studies leading to the regulatory approval of venetoclax, and discuss future investigation of this new class of antineoplastic agent.
Insights
Venetoclax, a BCL2-selective BH3 mimetic, is approved for chronic lymphocytic leukemia (CLL) and shows promise in other cancers. Further research will explore its potential in various hematologic malignancies and solid tumors.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- The BCL2 protein family regulates apoptosis, and its dysregulation is implicated in various cancers.
- Venetoclax is a novel BCL2-selective BH3 mimetic drug.
- Its efficacy has been demonstrated in chronic lymphocytic leukemia (CLL).
Approach:
- This review summarizes recent biological insights into BCL2 family members.
- It covers preclinical and clinical studies supporting venetoclax's approval.
- Future research directions for BH3 mimetics are discussed.
Key Points:
- Venetoclax targets BCL2, a key regulator of apoptosis.
- Regulatory approval was granted for relapsed, chromosome 17p-deleted CLL.
- Ongoing studies investigate venetoclax in lymphomas, acute leukemias, and solid tumors, both as monotherapy and in combination.
Conclusions:
- Venetoclax represents a new class of antineoplastic agents.
- Understanding BCL2 family biology is crucial for optimizing BH3 mimetic therapy.
- Expanded clinical investigation is warranted to define the full therapeutic potential of venetoclax.
More Related Videos
19:44Enhancement of Apoptotic and Autophagic Induction by a Novel Synthetic C-1 Analogue of 7-deoxypancratistatin in Human Breast Adenocarcinoma and Neuroblastoma Cells with Tamoxifen
Published on: May 30, 2012
13:20Detection of Mitochondria Membrane Potential to Study CLIC4 Knockdown-induced HN4 Cell Apoptosis In Vitro
Published on: July 17, 2018
Related Concept Videos
The Intrinsic Apoptotic Pathway
Apoptosis
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Autophagic Cell Death
Autophagy and Apoptosis
Autophagy can activate apoptosis. In normal conditions, the autophagy activating protein Beclin-1 and...
Mitochondrial Membranes
The Extrinsic Apoptotic Pathway